Splenic infarction secondary to multi‑site thrombosis in lung adenocarcinoma with EGFR‑L858R mutation: A case report

Wang,Qingsong; Zheng,He; Wang,Mingpu; Wei,Xiaoyu; Ma,Yuzhen; Wan,Zhengqiang

doi:10.3892/ol.2025.15163

Splenic infarction secondary to multi‑site thrombosis in lung adenocarcinoma with EGFR‑L858R mutation: A case report

Authors:
- Qingsong Wang
- He Zheng
- Mingpu Wang
- Xiaoyu Wei
- Yuzhen Ma
- Zhengqiang Wan
View Affiliations

Affiliations: Department of Thoracic Surgery, The First People's Hospital of Suining, Suining, Sichuan 264000, P.R. China, Department of Oral and Maxillofacial Surgery, The First People's Hospital of Suining, Suining, Sichuan 264000, P.R. China
Published online on: July 1, 2025 https://doi.org/10.3892/ol.2025.15163
Article Number: 417
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Venous thromboembolism (VTE) is a well‑documented complication in lung cancer; however, the culmination of multi‑site thrombosis in splenic infarction remains extremely rare. The present case report highlighted the complex interplay between oncogenic drivers and coagulation abnormalities in advanced non‑small cell lung cancer (NSCLC). A 37‑year‑old man with stage IVA (T3N2M1a) EGFR‑L858R‑mutated lung adenocarcinoma presented with acute left upper quadrant pain. Despite prophylactic anticoagulation with rivaroxaban (10 mg twice daily), imaging indicated progressive thrombosis involving the splenic artery, superior vena cava, and deep veins of the neck and lower extremities. Contrast‑enhanced abdominal CT confirmed splenic infarction without secondary abscess formation. The patient underwent intensified anticoagulation with enoxaparin (8,000 IU twice daily) and anti‑infective prophylaxis, which achieved spontaneous splenic infarct resolution on follow‑up imaging (December 2024 to May 2025). The present case underscored three critical clinical insights: i) The paradoxical thrombotic risk profile associated with EGFR‑mutated NSCLC during disease progression; ii) the limitations of current VTE risk assessment tools in advanced malignancies; and iii) the necessity for dynamic anticoagulation strategies in cancer‑associated thrombosis. Clinicians are advised to maintain heightened vigilance for thrombotic complications even in genetically defined NSCLC subsets (such as EGFR‑L858R mutant lung adenocarcinoma) receiving targeted therapies in the future.

View Figures

View References

1	Ruiz-Artacho P, Lecumberri R, Trujillo-Santos J, Font C, Lopez-Nunez JJ, Peris ML, Pedroche CD, Lobo JL, Jimenez LL, Reyes RL, et al: Cancer histology and natural history of patients with lung cancer and venous thromboembolism. Cancers (Basel). 14:41272022. View Article : Google Scholar : PubMed/NCBI
2	Hojbjerg JA, Bentsen KK, Vinholt PJ, Hansen O, Jeppesen SS and Hvas AM: Increased in vivo thrombin generation in patients with localized non-small cell lung cancer unfit for surgery. Clin Appl Thromb Hemost. 29:107602962311528972023. View Article : Google Scholar : PubMed/NCBI
3	Lobo FT, Alves R, Judas T and Delerue MF: Marantic endocarditis and paraneoplastic pulmonary embolism. BMJ Case Rep. 2017:bcr20172202172017. View Article : Google Scholar
4	Lysov Z, Swystun LL, Kuruvilla S, Arnold A and Liaw PC: Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption. Blood Coagul Fibrinolysis. 26:36–45. 2015. View Article : Google Scholar : PubMed/NCBI
5	Xu B, Zhang J, Tang S, Hou J and Ma M: Comparison of two types of catheters through femoral vein catheterization in patients with lung cancer undergoing chemotherapy: A retrospective study. J Vasc Access. 19:651–657. 2018. View Article : Google Scholar : PubMed/NCBI
6	Dou F, Li H, Zhu M, Liang L and Zhang Y, Yi J and Zhang Y: Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer. Respir Res. 19:882018. View Article : Google Scholar : PubMed/NCBI
7	Davidsson E, Murgia N, Ortiz-Villalon C, Wiklundh E, Skold M, Kolbeck KG and Ferrara G: Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma. Multidiscip Respir Med. 12:162017. View Article : Google Scholar : PubMed/NCBI
8	Schattner A, Adi M, Kitroser E and Klepfish A: Acute splenic infarction at an academic general hospital over 10 years. Medicine (Baltimore). 94:e13632015. View Article : Google Scholar : PubMed/NCBI
9	Abdallah A, Kaur V, Mahmoud F and Motwani P: Image diagnosis: Splenic infarction associated with oral contraceptive pills in a healthy young woman. Perm J. 21:16–071. 2017. View Article : Google Scholar
10	He YA, Wang DX, Lin LJ and Zheng CQ: Report of a case of splenic infarction and review of the literature. J Gastroenterol Hepatol. 29:239–240. 2020.
11	Yin X, He T, Hu H, Sun J and Xu Y: Report of a case of splenic arteriovenous embolism resulting in necrosis of the stomach, spleen and pancreatic body tail. Chin J Mod Operative Surg. 28:434–435. 2024.(In Chinese).
12	Brett AS, Azizzadeh N, Miller EM, Collins RJ, Seegars MB and Marcus MA: Assessment of clinical conditions associated with splenic infarction in adult patients. JAMA Intern Med. 180:1125–1128. 2020. View Article : Google Scholar : PubMed/NCBI
13	Fang Q, Tang M, Chang X, He M, Liu Y and Yin S: Construction and assessment of a Nomogram model for lung cancer patients with concurrent deep vein thrombosis. Chinese Journal of New Clinical Medicine. 17:1019–1025. 2024.(In Chinese).
14	Square F, Fu XG and Li YB: Deep vein thrombosis in the lower limbs of elderly lung cancer patients and its influencing factors. J Pract Cancer. 39:612–614. 2024.
15	Di W, Xu H, Ling C and Xue T: Early identification of lung cancer patients with venous thromboembolism: Development and validation of a risk prediction model. Thromb J. 21:952023. View Article : Google Scholar : PubMed/NCBI
16	Wang X and Zhi X: Introduction to the 8th edition of the TNM Classification of the Internatinoal Association for the Study of Lung Cancer (IASLC). Chin J Tharac Surg. 3:70–76. 2016.(In Chinese).
17	Writing Expert Group National Expert Committee on Capacity Building Project for Prevention and Treatment of Pulmonary Embolism and Deep Vein Thrombosis: Quality Evaluation and Management Guidelines for Prevention and Treatment of Venous Thromboembolism in Hospitals (2022 Edition). Natl Med J China. 102:3338–3348. 2022.(In Chinese).
18	Li J, Yan S, Zhang X, Xiang M, Zhang C, Gu L, Wei X, You C, Chen S, Zeng D and Jiang J: Circulating D-dimers increase the risk of mortality and venous thromboembolism in patients with lung cancer: A systematic analysis combined with external validation. Front Med (Lausanne). 9:8539412022. View Article : Google Scholar : PubMed/NCBI
19	Sanfilippo KM, Fiala MA, Feinberg D, Tathireddy H, Girard T, Vij R, Di Paola J and Gage BF: D-dimer predicts venous thromboembolism in multiple myeloma: A nested case-control study. Res Pract Thromb Haemost. 7:1022352023. View Article : Google Scholar : PubMed/NCBI
20	Yamanaka Y, Sawai Y and Nomura S: Platelet-derived microparticles are an important biomarker in patients with cancer-associated thrombosis. Int J Gen Med. 12:491–497. 2019. View Article : Google Scholar : PubMed/NCBI
21	Lin C, Xu XQ, He SD and Hong T: Clinical analysis of 21 cases of splenic infarction. J Chin Acad Med Sci. 36:321–323. 2014.
22	Levy JH, Shaw JR, Castellucci LA, Connors JM, Douketis J, Lindhoff-Last E, Rocca B, Samama CM, Siegal D and Weitz JI: Reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH. J Thromb Haemost. 22:2889–2899. 2024. View Article : Google Scholar : PubMed/NCBI
23	Cao L, Duan Z, Zhang T, Yuan R and Wang G: Progress of Study on Malignant Tumors and Thrombogenesis. Progress in Modern Biomedicine. 16:2187–2190. 2016.(In Chinese).
24	Wei R: Risk factors and treatment analysis of combined venous thromboembolism in lung cancer chemotherapy patients. J Clin Med. 4:15085–15086. 2017.(In Chinese).
25	Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F and Lee AYY: Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 8:112022. View Article : Google Scholar : PubMed/NCBI
26	Cheng Y, Cai X and Liu JW: Malignant tumours and thrombosis. J Clin Oncol. 15:376–379. 2010.
27	Wang D, Xiong W and Han F: Advances in the pathogenesis of venous thromboembolism associated with lung cancer. Chinese Journal of Respiratory and Critical Care. 22:135–141. 2023.(In Chinese).
28	Zhang M, Wu S and Hu C: Do lung cancer patients require routine anticoagulation treatment? A meta-analysis. J Int Med Res. 48:3000605198969192020. View Article : Google Scholar : PubMed/NCBI
29	Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, et al: Prospective assessment of clinical risk factors and biomarkers of hypercoagulability for the identification of patients with lung adenocarcinoma at risk for cancer-associated thrombosis: The observational ROADMAP-CAT study. Oncologist. 23:1372–1381. 2018. View Article : Google Scholar : PubMed/NCBI
30	Tang L, Liu XQ, Chen J, Bai Y, Li J, Zhang YD and Liu QX: Reducing the incidence of postoperative venous thromboembolism in patients with lung cancer. China Health Quality Management. 28:66–70. 2021.(In Chinese).
31	Hao EE and Jia Q: Correlation between coagulation function and tumour metastatic recurrence in non-small cell lung cancer patients. Thromb Haemost. 28:967–969. 2022.
32	Cukic V and Ustamujic A: Lung cancer and pulmonary thromboembolism. Mater Sociomed. 27:351–353. 2015. View Article : Google Scholar : PubMed/NCBI
33	Takemoto T, Soh J, Ohara S, Fujino T, Koga T, Nishino M, Hamada A, Chiba M, Shimoji M, Suda K, et al: The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery. Surg Today. 51:1480–1487. 2021. View Article : Google Scholar : PubMed/NCBI
34	Meikle CK, Meisler AJ, Bird CM, Jeffries JA, Azeem N, Garg P, Crawford EL, Kelly CA, Gao TZ, Wuescher LM, et al: Platelet-T cell aggregates in lung cancer patients: Implications for thrombosis. PLoS One. 15:e02369662020. View Article : Google Scholar : PubMed/NCBI
35	Minnelli C, Cianfruglia L, Laudadio E, Mobbili G, Galeazzi R and Armeni T: Effect of epigallocatechin-3-Gallate on EGFR signaling and migration in non-small cell lung cancer. Int J Mol Sci. 22:118332021. View Article : Google Scholar : PubMed/NCBI
36	Saryeddine L, Zibara K, Kassem N, Badran B and El-Zein N: EGF-induced VEGF exerts a PI3K-dependent positive feedback on ERK and AKT through VEGFR2 in hematological in vitro models. PLoS One. 11:e01658762016. View Article : Google Scholar : PubMed/NCBI
37	Hamza MS and Mousa SA: Cancer-Associated thrombosis: Risk factors, molecular mechanisms, future management. Clin Appl Thromb Hemost. 26:10760296209542822020. View Article : Google Scholar : PubMed/NCBI
38	Akinbo DB and Ajayi OI: Thrombotic pathogenesis and laboratory diagnosis in cancer patients, an update. Int J Gen Med. 16:259–272. 2023. View Article : Google Scholar : PubMed/NCBI
39	Xiao M, Pang C, Xiang S, Zhao Y, Wu X, Li M, Du F, Chen Y, Wang F, Wen Q, et al: Comprehensive characterization of B7 family members in NSCLC and identification of its regulatory network. Sci Rep. 13:43112023. View Article : Google Scholar : PubMed/NCBI
40	Durica SS: Venous thromboembolism in the cancer patient. Curr Opin Hematol. 4:306–311. 1997. View Article : Google Scholar : PubMed/NCBI
41	Chen P, Wan G and Zhu B: Incidence and risk factors of symptomatic thrombosis related to peripherally inserted central catheter in patients with lung cancer. J Adv Nurs. 77:1284–1292. 2021. View Article : Google Scholar : PubMed/NCBI
42	Feng Y, Fu Y, Xiang Q, Xie L, Yu C and Li J: Plasminogen activator inhibitor-1 gene promoter 4G/5G polymorphism and risks of peripherally inserted central catheter-related venous thrombosis in patients with lung cancer: A prospective cohort study. Support Care Cancer. 29:6431–6439. 2021. View Article : Google Scholar : PubMed/NCBI
43	Gao S, Sun S and Song J: Recent advances in the pathogenesis and treatment of malignant pericardial effusion. China Research Hospitals. 12:62–67. 2025.(In Chinese).
44	Hu YX, Jiang Y, Yan J and Liu JL: Treatment and prognosis of lung cancer with malignant pericardial effusion in emergency setting. Acad J Sec Mil Med Univ. 30:583–585. 2009. View Article : Google Scholar
45	Suwanwongse K and Shabarek N: Atrial flutter as an initial presentation of malignant pericardial effusion caused by lung cancer. Cureus. 12:e117122020.PubMed/NCBI
46	Dequanter D, Lothaire P, Berghmans T and Sculier JP: Severe pericardial effusion in patients with concurrent malignancy: A retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol. 15:3268–3271. 2008. View Article : Google Scholar : PubMed/NCBI
47	Sundar R, Soong R, Cho B, Brahmer JR and Soo RA: Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer. 85:101–109. 2014. View Article : Google Scholar : PubMed/NCBI
48	Vakamudi S, Ho N and Cremer PC: Pericardial effusions: Causes, diagnosis, and management. Prog Cardiovasc Dis. 59:380–388. 2017. View Article : Google Scholar : PubMed/NCBI
49	Qiu J, Xu L, Zeng X, Wu Z, Wang Y, Wang Y, Yang J, Wu H, Xie Y, Liang F, et al: NUSAP1 promotes the metastasis of breast cancer cells via the AMPK/PPARgamma signaling pathway. Ann Transl Med. 9:16892021. View Article : Google Scholar : PubMed/NCBI
50	Hu ZG, Hu K, Li WX and Zeng FJ: Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion. PLoS One. 14:e02170072019. View Article : Google Scholar : PubMed/NCBI
51	Goel K, Ateeli H, Ampel NM and L'Heureux D: Patient with small cell lung carcinoma and suspected right upper lobe abscess presenting with a purulent pericardial effusion. Am J Case Rep. 17:523–528. 2016. View Article : Google Scholar : PubMed/NCBI
52	Chiruvella V, Ullah A, Elhelf I, Patel N and Karim NA: Would the addition of immunotherapy impact the prognosis of patients with malignant pericardial effusion? Front Oncol. 12:8711322022. View Article : Google Scholar : PubMed/NCBI
53	Krolczyk G, Zabczyk M, Czyzewicz G, Plens K, Prior S, Butenas S and Undas A: Altered fibrin clot properties in advanced lung cancer: Impact of chemotherapy. J Thorac Dis. 10:6863–6872. 2018. View Article : Google Scholar : PubMed/NCBI
54	Koyama N, Tomoda K, Matsuda M, Fujita Y, Yamamoto Y, Hontsu S, Tasaki M, Yoshikawa M and Kimura H: Acute bilateral renal and splenic infarctions occurring during chemotherapy for lung cancer. Intern Med. 55:3635–3639. 2016. View Article : Google Scholar : PubMed/NCBI
55	Wang YL and Fan XZ: A case of splenic infarction initiated by upper abdominal pain. Clinical Focus. 29:209–210. 2014.(In Chinese).
56	Grant-Freemantle MC, Bass GA, Butt WT and Gillis AE: Splenectomy for isolated splenic metastasis from primary lung adenocarcinoma. BMJ Case Rep. 13:e2332562020. View Article : Google Scholar : PubMed/NCBI